Evidence map›Paper›PMID 29914578›Full record

ArticleJournal for immunotherapy of cancer2018

Near complete response to Pembrolizumab in microsatellite-stable metastatic sebaceous carcinoma.

Evidio Domingo-Musibay, Paari Murugan, Alessio Giubellino, Sandeep Sharma, Daniel Steinberger, Jianling Yuan, Matthew A Hunt, Emil Lou, Jeffrey S Miller

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 70 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Observational
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Evidio Domingo-MusibayDepartment of Medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota, 420 Delaware Street SE, MMC480, Minneapolis, MN, 55455, USA. musib024@umn.edu.ORCID 0000-0002-2082-554X
Paari MuruganDepartment of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, 55455, USA.
Alessio GiubellinoDepartment of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, 55455, USA.
Sandeep SharmaDepartment of Radiology, University of Minnesota, Minneapolis, MN, 55455, USA.
Daniel SteinbergerDepartment of Radiology, University of Minnesota, Minneapolis, MN, 55455, USA.
Jianling YuanDepartment of Radiation Oncology, University of Minnesota, Minneapolis, MN, 55455, USA.
Matthew A HuntDepartment of Neurosurgery, University of Minnesota, Minneapolis, MN, 55455, USA.
Emil LouDepartment of Medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota, 420 Delaware Street SE, MMC480, Minneapolis, MN, 55455, USA.
Jeffrey S MillerDepartment of Medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota, 420 Delaware Street SE, MMC480, Minneapolis, MN, 55455, USA.
University of Minnesota · USUniversity of Minnesota System · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSebaceous carcinoma is an aggressive adnexal skin tumor with a predilection for the eyelids and sebaceous glands of the head and neck. CASE PRESENTATION: A 73 year-old man presented with confusion and was found to have widely disseminated sebaceous carcinoma with metastases to brain, lungs, liver, bowel, lymph nodes, and bone. Following initial treatment of the brain metastases with surgery he received post-operative radiosurgery. He then began systemic immunotherapy with pembrolizumab. After 6 months, he developed a near complete response to therapy by irRECIST and RECIST v.1.1. The response was associated with circulating CD8+ T cells with central memory (CM) and effector memory (EM) phenotype and mature CD16 + CD57+ NK cells. During treatment the patient developed adrenal insufficiency requiring high-dose systemic corticosteroids and later adrenal replacement therapy. After 12-months of follow-up he showed imaging evidence of progression in liver, mediastinum, and abdominal lymph nodes. Given persistent, strong PD-L1 expression he resumed pembrolizumab therapy and showed radiographic evidence of an ongoing response to therapy.

conclusionsThis is the first report describing objective clinical and radiographic responses following immunotherapy for widely metastatic sebaceous carcinoma. The dramatic therapeutic response to pembrolizumab was associated with peripheral blood circulating memory T cells and mature Natural Killer cells after 6 months (24 weeks) of therapy. This report supports prospective clinical trials of anti-PD1 checkpoint blockade for metastatic sebaceous carcinoma.

Indexed as

AgedAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalHumansMaleMicrosatellite RepeatsPositron Emission Tomography Computed TomographyProgrammed Cell Death 1 ReceptorSebaceous Gland NeoplasmsSequence Analysis, DNATreatment OutcomeAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalPDCD1 protein, humanpembrolizumabProgrammed Cell Death 1 ReceptorAnti-PD1ImmunotherapyPembrolizumabSebaceous carcinomaSkin cancer5

Identifiers

PMID29914578
PMCPMC6006706
OpenAlexW2808965536

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.